rion and 2 with the combined RCV criterion, giving specificities of 0.825 (confidence interval, 0.677-0.916) and 0.965 (0.851-0.995), respectively.
• Include the RCV calculations for the combination of significant analytes for the pathology studied in the laboratory data processing system • Mark the test results showing a significant RCV with respect to the previous result • Include in the report a plot showing evolution of the analytes with a critical role in detecting changes in the pathology monitored A limitation of our RCV model to detect changes in the evolution of kidney graft recipients during monitoring is that it can only be applied to patients who have experienced a certain period of favorable clinical evolution. Regarding the usefulness of the model, we mention a few points. First, although the model can benefit only patients who have achieved an interval of clinical stability, these are precisely the ones in whom surveillance may be more relaxed (the patient has recovered from the operation and feels better; analyses are less frequent), and a specific, objective biochemical marker could be of greatest value. Second, the constituents providing an early indicator of rejection are among those analyzed in the standard protocol and at exactly the same frequency. Thus, no additional cost, effort, or discomfort to the patient is implied by the use of this approach (14 ) .
For the last 20 years, the most widely used method for assessment of the renin-angiotensin system has been the plasma renin activity assay (1 ) . Although the assay gives useful information on the enzymatic function of the renin molecule, the intrinsic characteristics of this method limit its analytical accuracy (2 ) . Immunoradiometric assays for renin, developed in 1985, overcame this limitation of the enzymatic assay because the well-defined monoclonal antibodies provided the means for direct quantification of specific active forms of the enzyme molecule (3, 4 ) . Nevertheless, a critical debate has developed over the use of these assays (5) (6) (7) (8) (9) (10) .
A pilot study (11, 12 ) in a limited number of laboratories (eight Italian centers) found satisfactory indexes of precision for a direct immunoradiometric renin assay (Eria Diagnostics, Sanofi-Pasteur). In our previous experience, the inter-and intralaboratory reproducibility indices of this commercial immunoradiometric assay appeared to be better than those that had been achieved with an enzymatic assay (REN-CTK; Sorin Biomedica), with the differences probably being attributable to the greater complexity of the procedure for the latter assay (11 ) .
Various reports have been published during the past 30 years describing useful tools to monitor the performance of immunoassays (13, 14 ) . Regarding the active renin assay, it is of paramount importance to assess the methodologic accuracy, especially for "low renin" concentrations, which are clinically relevant (15, 16 ) .
Here we describe the results of a supraregional qualitycontrol program, open to laboratories performing direct renin assays with a commercially available immunoradiometric method. The program included 48 clinical laboratories studied over a 12-month period with results provided periodically to the participants.
Forty-eight Italian laboratories participated in the first phase of the program, which included the determination of nine reference samples of unknown renin content (one every 3 weeks) during a 6-month period. Once a month a report with the extrapolated "consensus mean" and bias (expressed as SD) of the laboratory was sent to every participant, and at the end of each program a final report carried "precision" and "accuracy" results for the nine sample determinations. No results of this multicenter survey were rejected as outliers.
For the first phase of the program (June 1998 through January 1999), reference samples covering a wide concentration range were prepared from three pools of plasma samples collected for routine assays of renin activity. The three pools contained the following theoretic concentra- As in the first phase of the quality-control program, each pool was divided into three identical series of vials for a total of nine vials per set (each vial contained 0.75 mL of lyophilized plasma). The lyophilization process was the same as for the first phase.
This quality-control program was open to laboratories performing renin assays with the commercial immunoradiometric assay provided by Eria Diagnostics (SanofiPasteur). The first monoclonal antibody recognizes both the active and inactive forms of renin, whereas the second monoclonal antibody, labeled with 125 I, recognizes specifically the active form of renin. The tubes were counted in a gamma counter (Cobra AutoGamma; Camberra Packard), and the renin concentration of unknown samples was calculated from a calibration curve generated with Medical Research Council human renin (1 ng ϭ 1.6 ϫ 10 Ϫ3 GU; WHO 68/356). The detection limit of the assay was Ͻ1 ng/L for active renin at the half-life of the tracer. The interassay variation given by the manufacturer for renin concentrations of 8 -269 ng/L was 14.5-2.7%. Each laboratory also periodically received its accuracy indices with respect to a working consensus mean.
Interlaboratory CVs during the first phase were 14 -32% (Table 1) ; on the other hand, mean intralaboratory CVs for the same round, calculated for every laboratory on the three concentrations assayed three times, were 14 -19% (Table 1) . During the second phase, interlaboratory CVs were 16 -46% (Table 1) , and intralaboratory CVs for the second phase, calculated in the same way as for the first phase, were 16 -30% (Table 1) . The renin concentration range for the second phase included lower concentrations to allow evaluation of precision performance in this portion of the analytical interval.
The survey presented here involved a large group of participating laboratories (n ϭ 48) applying the same methodology. The long period of time over which the program was applied (12 months over 2 years) increased our confidence in the reliability of the results achieved. Although the present overall results confirm the previous good reproducibility data obtained with the same immunometric method (11 ) , the data reveal marked imprecision for lower renin concentrations. Blood concentrations of renin are particularly valuable and useful at low concentrations (18 ) and when the renin-angiotensin system is activated (15 ) . Because various immunometric assays for active renin are used for clinical research (15, 16, 19 ) , it would be advisable to validate each technique with a thorough quality-control program.
We are indebted to our colleagues at 48 Italian centers who participated in the present study.
